{"title":"Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1741","DOIUrl":null,"url":null,"abstract":"Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i5.1741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
